2 |
2
제 1 항에 있어서, 상기 N3 가 도입된 킬레이터는, 하기로부터 선택되는 것인, 방법:NOTA(1,4,7-triazacyclononane-1,4,7-triacetic acid), DOTA(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), DFO(3-[6,17-dihyroxy-7,10,18,21-tetraoxo-27-[N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane]thiourea), DTPA(diethylenetriaminepentaacetic acid), N2S2(diaminedithiol), p-SCN-Bn-NOTA(2-(4’-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid), NODAGA (1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid), p-SCN-Bn-DOTA(2-(4’-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), TETA(1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid), p-SCN-Bn-DTPA(2-(4-isothiocyanatobenzyl)-diethylenetriaminepentaacetic acid), p-SCN-Bn-DFO(1-(4-Isothiocyanatophenyl)-3-[6,17-dihyroxy-7,10,18,21-tetraoxo-27-[N-acetylhydroxylamino)-6,11,17,22-tetraazaheptaeicosane]thiourea),HYNIC(hydrazinonicotinic acid)
|
3 |
3
제 1 항에 있어서, 상기 킬레이터에 연결된 방사성동원원소는 18F, 68Ga, 64Cu, 89Zr, 124I, 감마선방출핵종인 99mTc, 111In, 123I, 125I, 또는 치료핵종인 67Cu, 177Lu, 90Y, 186Re, 188Re, 131I 중 어느 하나인 방법
|